医学
不利影响
肺癌
内科学
入射(几何)
临床终点
肿瘤科
阶段(地层学)
联合疗法
胃肠病学
随机对照试验
古生物学
物理
光学
生物
作者
Meng Wang,Meng-Xia Mao,Yaping Yang,Zhiqiang Cai,Yan Li,Yuanyuan Chen,Jun Cai,Qingqing Ye
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-08-01
卷期号:19 (25): 1729-1739
标识
DOI:10.2217/fon-2023-0470
摘要
Objective: To investigate the safety and efficacy of anlotinib hydrochloride capsules in stage III-IV non-small-cell lung cancer (NSCLC). Methods: NSCLC patients received anlotinib monotherapy or combination therapy. The primary end point was adverse reactions during anlotinib treatment and the secondary end point was progression-free survival. Results: During anlotinib treatement, 41.85% (167/399) of patients experienced adverse reactions, and the monotherapy group had a lower incidence than the combination group (36.89 vs 49.68%; p = 0.012). The median progression-free survival of patients in the monotherapy group was significantly lower than that in the combination group (5 vs 6 months; p = 0.0119). Conclusion: Compared with anlotinib monotherapy, combination therapy resulted in longer PFS and a higher incidence of adverse reactions in patients with NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI